RANGAP1

Across TCGA pan-cancer cohorts, RANGAP1 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated RANGAP1 data layer compared with 30 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher RANGAP1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RANGAP1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

PAAD, SARC, and BRCA are the cancer types where RANGAP1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	OS	Median	All	0.060	0.641	<.001	12	view →
SARC	OS	Median	All	0.085	0.839	<.001	12	view →
BRCA	OS	Median	All	0.107	0.578	.005	12	view →
LUSC	DFS	Median	III,IV	0.010	0.754	<.001	12	view →
COAD	OS	Median	III,IV	0.159	0.692	.021	7	view →
THCA	DFS	Median	All	0.144	0.829	.005	6	view →
CESC	DFS	Median	II,III,IV	0.193	0.705	.045	6	view →
BLCA	OS	Median	All	0.256	0.621	.033	6	view →
UCEC	DFS	Median	All	1.000	0.635	.032	4	view →
LUAD	OS	Median	All	0.276	0.697	.040	3	view →
SKCM	DFS	Median	III,IV	0.058	0.648	.001	3	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

RANGAP1–PAAD (OS)

Open the PAAD breakdown →